Botulism

Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts

Retrieved on: 
Tuesday, April 27, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Clinical medicine, Medicine, Medical specialties, Botulism, Botulinum toxin, Neurotoxins, Toxins, Clostridium botulinum, Botulinum toxin therapy of strabismus

It is generally accepted that as age increases, the efficacy of botulinum toxin decreases.

Key Points: 
  • It is generally accepted that as age increases, the efficacy of botulinum toxin decreases.
  • This has been demonstrated in multiple studies with current aesthetic botulinum toxin products.
  • A further analysis was performed on female subjects
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.

Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

Retrieved on: 
Tuesday, April 27, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Companies of China, Drugs, Companies, Botulinum toxin, Botulism, Neurotoxins, Toxins, Dystonia, Fosun Pharma, Spasticity, Spasmodic torticollis, Fosun International

Under the license agreement, Fosun Pharma Industrial is responsible for conducting necessary clinical studies, marketing and sales in the Territory, while Revance is responsible for manufacturing drug substance and finished drug product for Fosun Pharma Industrial\xe2\x80\x99s clinical and commercial activities.

Key Points: 
  • Under the license agreement, Fosun Pharma Industrial is responsible for conducting necessary clinical studies, marketing and sales in the Territory, while Revance is responsible for manufacturing drug substance and finished drug product for Fosun Pharma Industrial\xe2\x80\x99s clinical and commercial activities.
  • DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow\'s feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity.

Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021

Retrieved on: 
Friday, April 23, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Drugs, Pharmaceutical companies, Health care, Plastic surgery, Botulinum toxin, Botulism, Neurotoxins, XC2, Viatris, Mylan

\xe2\x80\x9cThese data continue to underscore the innovation that drives Revance\xe2\x80\x99s aesthetics portfolio, including our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, and the RHA\xc2\xae Collection, which was launched in September 2020.\xe2\x80\x9d\nThe abstracts are available online via the AAD VMX website at www.aad.org .

Key Points: 
  • \xe2\x80\x9cThese data continue to underscore the innovation that drives Revance\xe2\x80\x99s aesthetics portfolio, including our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, and the RHA\xc2\xae Collection, which was launched in September 2020.\xe2\x80\x9d\nThe abstracts are available online via the AAD VMX website at www.aad.org .
  • DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX\xc2\xae, which would compete in the existing short-acting neuromodulator marketplace.

Cosmeceuticals Market Size to Reach USD 781.8 Million by 2026 at CAGR 5.6% - Valuates Reports

Retrieved on: 
Tuesday, March 30, 2021
Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Compound annual growth rate, Cosmetics, Medical specialties

- The Cosmetics ODM market size is projected to reach USD 15590 Million by 2026, from USD 7705.5 Million in 2019, at a CAGR of 10.6% during 2021-2026.

Key Points: 
  • - The Cosmetics ODM market size is projected to reach USD 15590 Million by 2026, from USD 7705.5 Million in 2019, at a CAGR of 10.6% during 2021-2026.
  • - The Cosmetic Packaging market size is projected to reach USD 29720 Million by 2026, from USD 22690 Million in 2019, at a CAGR of 3.9% during 2021-2026.
  • - The Aesthetic/Cosmetic Lasers market size is projected to reach USD 1160 Million by 2026, from USD 668 Million in 2019, at a CAGR of 8.1% during 2021-2026.
  • - The Botulinum Toxin market size is projected to reach USD 12360 Million by 2026, from USD 5205.7 Million in 2019, at a CAGR of 13.0% during the forecast period 2021-2026.

Cosmeceuticals Market Size to Reach USD 781.8 Million by 2026 at CAGR 5.6% - Valuates Reports

Retrieved on: 
Tuesday, March 30, 2021
Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Compound annual growth rate, Cosmetics, Medical specialties

- The Cosmetics ODM market size is projected to reach USD 15590 Million by 2026, from USD 7705.5 Million in 2019, at a CAGR of 10.6% during 2021-2026.

Key Points: 
  • - The Cosmetics ODM market size is projected to reach USD 15590 Million by 2026, from USD 7705.5 Million in 2019, at a CAGR of 10.6% during 2021-2026.
  • - The Cosmetic Packaging market size is projected to reach USD 29720 Million by 2026, from USD 22690 Million in 2019, at a CAGR of 3.9% during 2021-2026.
  • - The Aesthetic/Cosmetic Lasers market size is projected to reach USD 1160 Million by 2026, from USD 668 Million in 2019, at a CAGR of 8.1% during 2021-2026.
  • - The Botulinum Toxin market size is projected to reach USD 12360 Million by 2026, from USD 5205.7 Million in 2019, at a CAGR of 13.0% during the forecast period 2021-2026.

Global $25+ Billion Facial Injectable Market to 2028: Botulinum Toxin Type A segment Led the Market in 2020 and is Projected to Dominate

Retrieved on: 
Monday, March 8, 2021
Medical specialties, Surgery, Surgical specialties, Plastic surgery, Botulism, Ageing, Skin, Wrinkle, Oral and maxillofacial surgery, Botulinum toxin, Hyaluronic acid, Injectable filler

The global facial injectable market size is expected to reach USD 27.7 billion by 2028.

Key Points: 
  • The global facial injectable market size is expected to reach USD 27.7 billion by 2028.
  • The facial injectable is a substance that is used to reduce wrinkles and restore volume and fullness in the face.
  • Some commonly used facial injectables include hyaluronic acid, botulinum toxin type A, and polymer fillers.
  • By product, the botulinum toxin type A segment led the market in 2020 and is projected to dominate throughout the forecast period.

Botulinum Toxin and Cosmetic Fillers (Children) Bill

Retrieved on: 
Friday, March 5, 2021
Clinical medicine, Medicine, Medical specialties, Botulism, Botulinum toxin, Neurotoxins, Toxins, Botulinum toxin therapy of strabismus, Clostridium botulinum

A Bill to make provision about the administration to persons under the age of 18 of botulinum toxin and of other substances for cosmetic purposes; and for connected purposes.

Key Points: 

A Bill to make provision about the administration to persons under the age of 18 of botulinum toxin and of other substances for cosmetic purposes; and for connected purposes.

Revance to Participate in Upcoming Virtual Healthcare Conferences

Retrieved on: 
Wednesday, February 24, 2021
Health, Other Health, Other Science, General Health, Research, Science, Biotechnology, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Toxicology

The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

Key Points: 
  • The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
  • Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • "Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 23, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Toxicology

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced new hire grants totaling 6,601 inducement restricted stock awards (RSAs) to 1 employee.

Key Points: 
  • Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced new hire grants totaling 6,601 inducement restricted stock awards (RSAs) to 1 employee.
  • Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    RHA resilient hyaluronic acid and RHA are trademarks of TEOXANE SA.

Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity

Retrieved on: 
Monday, February 22, 2021
Cosmetics, Retail, Health, Clinical trials, Pharmaceutical, Biotechnology, Drugs, Branches of biology, Medical specialties, Plastic surgery, Botulinum toxin, Botulism, Neurotoxins, Dystonia, Hyaluronic acid, Spasticity, Spasmodic torticollis, JUNIPER Phase 2 Study, Upper Limb Spasticity, Revance Therapeutics, Inc.

On a key secondary endpoint, DaxibotulinumtoxinA for Injection delivered a median duration of at least 24 weeks across all three doses.

Key Points: 
  • On a key secondary endpoint, DaxibotulinumtoxinA for Injection delivered a median duration of at least 24 weeks across all three doses.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity.
  • "Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.